In April 2025, the Company announced that the first patient had been dosed in Part 2a of the Phase 2 DENALI clinical trial ( NCT05128825) of azenosertib in patients with Cyclin E1+ platinum-resistant ...

ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three ...

Presentation Details Title: Anti-cancer effect of Cyclin A/B RxL inhibitors is mediated ... Marie Evangelista, and Pablo D. Garcia, Circle Pharma Inc., South San Francisco, CA, University of ...

"We are excited to continue the clinical development of azenosertib and are proud to take another step forward in addressing the significant unmet need in Cyclin E1+ PROC," said Ingmar Bruns, M.D ...

“Dosing the first patient in Part 2 of the DENALI study is an important milestone for Zentalis as we continue the clinical development of azenosertib,” said Ingmar Bruns, M.D., Chief Medical O ...

Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject ...

Researchers have introduced DiffSMol, a generative AI model capable of generating realistic 3D structures of small molecules ...

Pivotal Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline metastatic breast cancer on track for initiation in 2025, supported by promising updated efficacy data from ...

VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 ...

Cagnoni, M.D., President and Head of Research and Development ... Abstract #7184.)) Association of Cyclin E1 Expression with Genomic Instability in Ovarian Cancer (Session Title: Origins and ...

Learn more about whether BioCryst Pharmaceuticals, Inc. or Blueprint Medicines Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial ...

Moderate FDG uptake is present in a few thoracic lymph nodes (Panel D, white arrow ... of immunophenotypic aberrancy on plasma cells, cyclin D1 expression, bone marrow involvement, and other ...